[Is prescription of a therapy costing 150,000 CHF reasonable?]

The costs of medicinal products have increased substantially in the last decade. Access to medical innovations for all patients is in acute danger. This situation requires a political commitment by the wider community of caregivers, healthcare providers and industry. New pricing models are inevitable to garantee access to medical innovation for all people in our society. Further, we must require companies to be more transparent when setting drug prices and require an attitude of consensus on prices between these industries - financially sound. Finally, our health insurance system must accept some state control to avoid patient selection, but also know the precise margin of manoeuvre over time in terms of cost expenditures assigned to oncology.